On August 21 the board of Alteogen Inc. (KOSDAQ: 196170) signed off on a new plant in the Dunkok district of Daejeon. The bill is ₩253.2 billion, spread over three years to a scheduled completion in September 2028. The filing does the awkward arithmetic for you: that's 55.7% of consolidated equity as of the 2025 close. Sixteen days earlier the same company had announced an exclusive license worth up to $365 million in upfront and milestone payments, royalties on top, counterparty withheld.
Read the two filings together and you have the thesis. Alteogen's income statement is about as clean a licensing P&L as exists in Korean biotech, and the market is paying for precisely that. Management has now committed to spending like a manufacturer. However that turns out, the margin structure investors are underwriting today isn't the one this company will have in 2029.
Alteogen makes an enzyme called ALT-B4, a recombinant human hyaluronidase, marketed under the Hybrozyme platform name. The enzyme temporarily loosens tissue under the skin so that a large-volume antibody drug, which normally requires a half-hour infusion in a chair, can be pushed in as an injection in a couple of minutes. The best-known application is Merck's Keytruda Qlex, the subcutaneous version of the world's biggest-selling cancer drug. Merck reported $463 million of Qlex sales in the June quarter against $128 million in the March quarter, and told investors that the subcutaneous form has already reached a double-digit share of US Keytruda volume.
What matters for reading the financials is what Alteogen books off that. It doesn't sell Keytruda. It collects a payment when a partner signs, more payments as that partner clears development and regulatory hurdles, and a percentage of net sales once a product launches. The August 5 filing is a good specimen of the model. Up to $365 million in upfront and milestones, worth about ₩521.9 billion at the ₩1,429.90 rate the company used, with the sales royalty stated as a separate and undisclosed percentage. The upfront was due within thirty days of the August 5 effective date, so it belongs to the third quarter. Alteogen also disclosed, plainly, that none of what it receives is refundable, and that the partner can walk away at its own convenience.
That was the third such deal of 2026. GSK's Tesaro took a license for a subcutaneous dostarlimab in January, Biogen took one covering two biologics in March, and the August partner is unnamed under a confidentiality carve-out that also hides the product, the upfront and the royalty rate. Which is a real limitation for anyone trying to model this: you're told the ceiling and nothing about the slope.
June-quarter revenue was ₩68.9 billion. Cost of revenue against it was ₩7.4 billion, so gross profit came to ₩61.5 billion, an 89% gross margin. Operating income of ₩34.2 billion gives a 49.6% operating margin. Pharmaceutical manufacturers do not earn that. Software companies and royalty vehicles do.
The gap between the 89% gross line and the 49.6% operating line is almost entirely SG&A, which was ₩27.3 billion in the quarter against ₩12.5 billion a year earlier. Alteogen is spending more than twice as much to run itself as it was twelve months ago, and it's still the case that on this revenue base the operating margin barely moved from the 49.5% the company earned for full-year 2025.
The other thing the quarterly series shows is how uneven the top line is. In the June quarter of 2025 Alteogen booked ₩18.6 billion of revenue and lost ₩0.4 billion at the operating line. Two quarters before that, in March 2025, it booked ₩83.7 billion and earned ₩61.0 billion. First-half 2026 revenue of ₩140.5 billion against ₩102.3 billion a year earlier looks like tidy 37% growth, but the quarterly path underneath it is a staircase built out of contract signings. That's normal for the model and it's a poor foundation for extrapolating any single quarter.
One line deserves more attention than it gets. Trailing twelve-month net income is roughly ₩197.7 billion, and inside it sits about ₩85.8 billion of finance income against ₩15.0 billion of finance costs. December quarter finance income alone was ₩48.6 billion, March quarter ₩35.9 billion. In the June quarter that line turned negative, at minus ₩1.7 billion. Whatever is driving it, and the summary figures don't say, it is not the licensing business, it swings hard, and it accounts for a large share of the earnings number the P/E is calculated on. Trailing operating income is ₩119.8 billion. That's the number I'd anchor to.
The plant is what changes the shape of this company. ₩253.2 billion covers buildings, equipment and machinery, is scheduled to run from August 2026 to September 2028, and is described as capacity for biologics manufacturing and global market response. Against second-quarter equity of ₩547.2 billion rather than the 2025 figure the filing uses, it's closer to 46%, though that hardly softens it.
Alteogen can pay for it. Cash and equivalents stood at ₩80.4 billion at the end of June, inside ₩521.9 billion of current assets whose composition the summary figures don't break out, and total liabilities of ₩192.7 billion against total assets of ₩739.9 billion leave the balance sheet unlevered. Operating cash flow was ₩124.1 billion for 2025 and ₩37.6 billion across the first half of 2026. The August license, if the milestones land, is worth up to twice the cost of the plant on its own. Funding isn't the question.
The question is what the plant does to the margin. Property, plant and equipment has already gone from ₩19.2 billion at the end of 2024 to ₩40.4 billion at the end of 2025 to ₩55.5 billion in June. Inventories went from ₩1.0 billion to ₩6.5 billion over the same stretch. A company that only licenses intellectual property does not carry rising inventory. Something is being made and shipped already, which is consistent with the lumpy cost of revenue line, ₩21.9 billion in the December quarter against ₩7.4 billion in June.
So there's a plausible reading in which the factory is straightforwardly good. If Alteogen supplies the enzyme itself to a growing list of partners rather than sublicensing manufacturing, it captures supply revenue on top of royalties and controls quality on a molecule several large partners now depend on. There's also a reading in which it's a margin event. Depreciation on ₩253.2 billion, plus the fixed cost of running a plant, lands on an operating line that today only has to cover salaries and research. On current revenue, a full year of depreciation on that asset base would be visible.
At the August 28 close of ₩320,000, Alteogen carries a market capitalization of ₩22.29 trillion on 69.7 million shares, following the 30% bonus issue that went ex on August 4. That's 112.7 times trailing earnings and 40.7 times book. Against trailing operating income of ₩119.8 billion, it's about 186 times.
Those multiples are not defensible on current cash flow and aren't meant to be. What they price is the royalty stream that hasn't arrived yet. Qlex is early. If subcutaneous conversion reaches the 30% to 40% of US Keytruda that Merck has pointed to for end-2027, and if the other licensed programs launch, the royalty base compounds against a cost base that barely moves. That's the bull case, and it's a coherent one. It just requires the cost base to barely move, which is the assumption the August 21 board resolution starts to complicate.
The patent overhang hasn't cleared, it has fragmented. Halozyme sued Merck in New Jersey in April 2025 over its MDASE family of modified hyaluronidase patents, and Alteogen's defence has been that ALT-B4 was developed independently and its sequence appears in none of them. The US Patent Trial and Appeal Board invalidated one of the challenged patents in May 2026, and a Dutch court declined to grant an injunction. In Germany, Halozyme won a preliminary injunction that blocked the Keytruda SC launch. A royalty is a claim on someone else's sales, and it inherits every jurisdiction those sales run through.
Concentration is the second problem. Merck is the anchor, and the two most recent partners are large but the products behind the licenses are unnamed. Alteogen's revenue in any given quarter is a function of contract events it doesn't fully control and can't always disclose.
Third, and this is the one that could bite soonest, none of the figures above tell you the royalty rate on anything. A reader can watch Qlex revenue climb at Merck and still have no way to convert it into won. The company's July decision to put its planned move to the main KOSPI board on hold, disclosed on July 16 without a stated reason, doesn't help the disclosure picture either.
The third-quarter report, due in November, should carry the ALT-B4 upfront, and the size of it will be the first hard read on what a 2026-vintage Alteogen license is actually worth rather than what its ceiling is. Watch two lines underneath it. Cost of revenue and inventories will show whether the supply business is scaling ahead of the plant, and the purchase of property, plant and equipment line, which was ₩13.9 billion in March and ₩2.4 billion in June, will show how fast the ₩253.2 billion is actually going out the door against the three-year schedule the company gave. Merck's third-quarter Qlex number, against the $463 million it just posted, is the other one. If that keeps compounding while cost of revenue stays near ₩7 billion a quarter, the asset-light story survives its own factory.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.